Search Within

Maria Michelle Rubinstein

Formats
  1. Journal Article (22)
  2. Meeting Abstract (13)
  3. Review (4)
Groups
  1. GDMT, Medicine (39)
  2. Gynecologic Medicine Service (39)
  3. Gynecology Disease Management Team (39)
  4. Solid Tumor Oncology Division (39)
  5. Weinberg Fellows (39)
  6. Department of Medicine (33)

More Groups

People
  1. Vicky Makker (28)
  2. Carol Aghajanian (21)
  3. Alexia Iasonos (15)
  4. Rachel Grisham (15)
  5. Britta Weigelt (13)
  6. Claire Friedman (13)

More People

Years
  1. 2025 (6)
  2. 2024 (5)
  3. 2023 (8)
  4. 2022 (6)
  5. 2021 (5)
  6. 2020 (5)

More Years

Publications
  1. Gynecologic Oncology (13)
  2. International Journal of Gynecological Cancer (5)
  3. Journal of Clinical Oncology (5)
  4. Gynecologic Oncology Reports (3)
  5. Clinical Cancer Research (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. Elsevier B.V. (16)
  2. Lippincott Williams & Wilkins (7)
  3. American Society of Clinical Oncology (5)
  4. American Association for Cancer Research (3)
  5. Nature Publishing Group (2)
  6. Oxford University Press (2)

More Publishers

Results (39)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
    Journal Article

    Lumish, M.; Chui, M. H.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Cohen, S.; Friedman, C.; Grisham, R.; Konner, J.; Kyi, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
    Meeting Abstract

    Marathe, O.; Cheng, Y.; Spira, A. I.; Hamilton, E. P.; Rubinstein, M. M.; Dong, X.; Li, L.; Lv, D.; Shi, J.; Gabrail, N.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Germline drivers of gynecologic carcinosarcoma
    Meeting Abstract

    Sia, T.; Birsoy, O.; Kemel, Y.; Maio, A.; Salo-Mullen, E.; Sheehan, M.; Hensley, M.; Rubinstein, M.; Makker, V.; Grisham, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Real-world outcomes and adverse events when using combination lenvatinib and pembrolizumab for the treatment of recurrent uterine cancer
    Meeting Abstract

    Zammarrelli, W.; Ma, W.; Espino, K.; Yeoshoua, E.; Ehmann, S.; Zhou, Q.; Iasonos, A.; Abu-Rustum, N.; Aghajanian, C.; Green, A.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma
    Meeting Abstract

    Liu, J.; Colombo, N.; Oza, A.; Frenel, J. S.; Corr, B.; Rubinstein, M.; Nevadunsky, N.; Lheureux, S.; Gaba, L.; Cortijo, L. G.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer
    Journal Article

    Zammarrelli, W. A. 3rd; Ma, W.; Espino, K.; Gordhandas, S.; Yeoshoua, E.; Ehmann, S.; Zhou, Q.; Iasonos, A.; Abu-Rustum, N. R.; Aghajanian, C.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Comprehensive analysis of germline drivers in endometrial cancer
    Journal Article

    Gordhandas, S.; Rios-Doria, E.; Cadoo, K. A.; Catchings, A.; Maio, A.; Kemel, Y.; Sheehan, M.; Ranganathan, M.; Green, D.; Aryamvally, A.; more...
    JNCI: Journal of the National Cancer Institute (2023)

    Fulltext@MSK | Save
  • Germline drivers of gynecologic carcinosarcomas
    Journal Article

    Sia, T. Y.; Gordhandas, S. B.; Birsoy, O.; Kemel, Y.; Maio, A.; Salo-Mullen, E.; Sheehan, M.; Hensley, M. L.; Rubinstein, M.; Makker, V.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
    Journal Article

    Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Real-world experience and common adverse events when using combination lenvatinib and pembrolizumab for the treatment of recurrent uterine cancer
    Meeting Abstract

    Zammarrelli, W.; Espino, K.; Yeoshoua, E.; Ehmann, S.; Rubinstein, M.; Green, A.; Makker, V.
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save